Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBT (2021 - 2025)

Historic EBT for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $48.0 million.

  • Krystal Biotech's EBT rose 6113.07% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.9 million, marking a year-over-year increase of 22567.81%. This contributed to the annual value of $95.4 million for FY2024, which is 63936.57% up from last year.
  • Per Krystal Biotech's latest filing, its EBT stood at $48.0 million for Q3 2025, which was up 6113.07% from $46.8 million recorded in Q2 2025.
  • Krystal Biotech's 5-year EBT high stood at $80.7 million for Q3 2023, and its period low was -$50.0 million during Q1 2022.
  • For the 5-year period, Krystal Biotech's EBT averaged around $1.9 million, with its median value being -$15.6 million (2021).
  • Its EBT has fluctuated over the past 5 years, first crashed by 21599.42% in 2022, then surged by 457778.97% in 2025.
  • Over the past 5 years, Krystal Biotech's EBT (Quarter) stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then surged by 133.25% to $10.7 million in 2023, then soared by 356.13% to $48.6 million in 2024, then fell by 1.32% to $48.0 million in 2025.
  • Its last three reported values are $48.0 million in Q3 2025, $46.8 million for Q2 2025, and $43.6 million during Q1 2025.